Edition:
United States

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

0.25USD
4:00pm EDT
Change (% chg)

$-0.03 (-11.46%)
Prev Close
$0.28
Open
$0.28
Day's High
$0.28
Day's Low
$0.22
Volume
73,109
Avg. Vol
104,337
52-wk High
$6.43
52-wk Low
$0.22

Chart for

About

Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and... (more)

Overall

Beta: -1.02
Market Cap(Mil.): $5.80
Shares Outstanding(Mil.): 20.65
Dividend: --
Yield (%): --

Financials

  KOOL.OQ Industry Sector
P/E (TTM): 0.38 28.29 30.45
EPS (TTM): 0.74 -- --
ROI: 14.67 12.92 12.63
ROE: 22.75 14.94 14.82

BRIEF-Cesca Prices $5.5 Million Public Offering

* CESCA THERAPEUTICS INC - IS OFFERING UNITS AT A PRICE OF $0.60 PER UNIT.

May 16 2018

BRIEF-Cesca Therapeutics Reports Q1 Loss Per Share $0.27

* CESCA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 14 2018

BRIEF-Cesca Therapeutics Says Offering Up To 3.2 Million Units

* CESCA THERAPEUTICS SAYS OFFERING UP TO 3.2 MILLION UNITS, EACH UNIT CONSISTING OF 1 SHARE OF COMMON STOCK, ONE COMMON WARRANT TO PURCHASE 1 SHARE OF STOCK Source text: (https://bit.ly/2I8M01T) Further company coverage:

May 08 2018

BRIEF-Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES EVALUATION AGREEMENT WITH THE UNIVERSITY OF NORTH CAROLINA LINEBERGER ADVANCED CELLULAR THERAPEUTICS FACILITY FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING

Apr 24 2018

BRIEF-Cesca Therapeutics Entered Amendment To Revolving Line Of Credit Facility

* CESCA THERAPEUTICS SAYS ON APRIL 16, ENTERED AMENDMENT TO ITS REVOLVING LINE OF CREDIT FACILITY - SEC FILING

Apr 18 2018

BRIEF-Cesca Therapeutics Announces First Evaluation Agreement With A Leading U.S. Academic Research Institution For X-Series Products

* CESCA THERAPEUTICS ANNOUNCES FIRST EVALUATION AGREEMENT WITH A LEADING U.S. ACADEMIC RESEARCH INSTITUTION FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING

Apr 17 2018

BRIEF-Cesca Therapeutics Announces Registered Direct Offering

* CESCA THERAPEUTICS INC - ‍PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS TO 609,636 SHARES OF STOCK AT A PURCHASE PRICE OF $2.27 PER SHARE​ Source text for Eikon: Further company coverage:

Mar 26 2018

BRIEF-Cesca Subsidiary Expands Into CAR-T Related Contract Development And Manufacturing

* CESCA’S DEVICE SUBSIDIARY, THERMOGENESIS, EXPANDS INTO CAR-T RELATED CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) SERVICES

Mar 14 2018

Earnings vs. Estimates